Myriad Genetics (MYGN) Posts Earnings Results

Myriad Genetics (NASDAQ:MYGN) released its quarterly earnings data on Tuesday. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.13, RTT News reports. Myriad Genetics had a net margin of 17.69% and a return on equity of 9.78%. The firm had revenue of $202.30 million for the quarter, compared to analyst estimates of $203.20 million. During the same period last year, the firm earned $0.26 earnings per share. The business’s quarterly revenue was up 13.1% compared to the same quarter last year.

Shares of MYGN stock traded down $3.51 on Wednesday, hitting $33.16. The stock had a trading volume of 44,320 shares, compared to its average volume of 990,836. The company has a market cap of $2.87 billion, a P/E ratio of 27.36, a P/E/G ratio of 2.36 and a beta of 0.51. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.19 and a quick ratio of 2.86. Myriad Genetics has a 12-month low of $27.27 and a 12-month high of $50.44.

MYGN has been the topic of a number of recent research reports. Piper Jaffray Companies raised shares of Myriad Genetics from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $38.00 to $53.00 in a research note on Wednesday, October 10th. Barclays raised their price objective on shares of Myriad Genetics from $35.00 to $38.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 22nd. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research note on Friday, August 24th. ValuEngine downgraded shares of Myriad Genetics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 12th. Finally, BidaskClub downgraded shares of Myriad Genetics from a “buy” rating to a “hold” rating in a report on Saturday. Three equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. Myriad Genetics presently has an average rating of “Hold” and an average price target of $41.90.

Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada increased its holdings in Myriad Genetics by 59.5% during the first quarter. Royal Bank of Canada now owns 4,597 shares of the company’s stock worth $136,000 after buying an additional 1,715 shares during the last quarter. Robecosam AG increased its holdings in Myriad Genetics by 39.8% during the second quarter. Robecosam AG now owns 4,193 shares of the company’s stock worth $156,000 after buying an additional 1,193 shares during the last quarter. First Quadrant L P CA purchased a new stake in Myriad Genetics during the third quarter worth about $201,000. Parametrica Management Ltd purchased a new stake in Myriad Genetics during the third quarter worth about $204,000. Finally, Commonwealth Equity Services LLC purchased a new stake in Myriad Genetics during the second quarter worth about $205,000. Institutional investors own 96.75% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Myriad Genetics (MYGN) Posts Earnings Results” was first published by WKRB News and is owned by of WKRB News. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://www.wkrb13.com/2018/11/07/myriad-genetics-mygn-posts-earnings-results.html.

About Myriad Genetics

Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.

Read More: Balance Sheet

Earnings History for Myriad Genetics (NASDAQ:MYGN)

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply